von Willebrand disease (vWD) variant type llB is an inherited bleeding disorder resulting from the spontaneous binding of defective von Willebrand factor (vWF) to platelets in vivo. To identify the molecular basis for type IIB vWD, we used reverse transcription and the polymerase chain reaction to examine the nucleotide sequence of the platelet glycoprotein (GP) Ib-binding domain encoded by the vWF messenger RNA in an affected family, and in an unrelated affected individual. We identified two different missense mutations linked with expression of type IIB vWD. These mutations, which lead to Pro5" --* Leu and Val5" -+ Met substitutions, respectively, were each introduced into the full-length vWF expression vector pvW198, and both wild-type (wt) and mutant vWF ON WILLEBRAND factor (vWF) is a multimeric V plasma glycoprotein (GP) with essential functions in hemostasis. In addition to stabilizing factor VI11 in plasma, vWF promotes adhesion of platelets to the subendothelium at the site of vascular injury through interaction with the platelet GPIb receptor.' Defects in vWF result in von Willebrand disease (vWD), which is the most common inherited bleeding disorder in humans. The prevalence of vWD has been estimated to be as high as 1% of the population.2 vWD is heterogeneous, and is classified based on quantitative deficiencies in vWF plasma levels (types I and III), or on qualitative abnormalities affecting vWF function (type 11). In total, over 20 subtypes of the disease have been identified.' vWD variant type IIB is characterized by the selective absence of the largest vWF multimers from plasma due to the increased affinity of the abnormal vWF for the GPIb receptor on platelet^?. ate and low mw vWF multimers of type IIB individuals show enhanced binding to normal platelets in vitro in the presence of low concentrations of the antibiotic ristocetin, unlike normal plasma vWF. Pseudo-or platelet-type vWD is clinically similar to type IIB vWD, but differs in that the defect resulting in the abnormal vWF/GPIb interaction resides in GPIb.6 Analysis of tryptic fragments of vWF localized the GPIb-binding domain to amino acids 449 to 718 of the mature vWF subunit.'-' These amino acids are included in the A1 domain of vWF and are encoded by exon 28 of the vWF gene.'" Using RNA polymerase chain reaction (PCR) and transient expression of full-length vWF, Ginsburg et al" identified a missense mutation in exon 28 responsible for the expression of another variant of vWD, type IIA. Using a similar strategy, we identified two missense mutations within exon 28 that are linked with expression of type IIB vWD, and have shown that these mutations each confer to expressed full-length vWF a greater affinity for platelet GPIb, which is consistent with the type IIB vWD phenotype.
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MATERIALS AND METHODS
Isolation of total cellular RNA and genomic DNA. Total cellular RNA and genomic DNA were prepared from platelets and leukocytes, respectively, isolated from 50 mL of peripheral blood by differential centrifugation. RNA was obtained from platelets after lysis in the presence of guanidinium isothiocyanate and purified by centrifugation through CsCl as described by Newman et al,'* with the modifications noted below. In brief, prostaglandin E, (PGE,; Sigma Chemical Co, St Louis, MO) was added to plateletrich plasma to a final concentration of 50 ng/mL, and platelets were recovered by centrifugation (90Og for 10 minutes). Platelets were washed once in 10 mL of Phillips' buffer (96.5 mmol/L NaC1, 85.7 mmol/L glucose, 1.1 mmol/L EDTA, 8.5 mmol/L Tris-HCl, pH 7.4) containing 50 ng/mL of PGE,, and then lysed in 3.0 mL of a solution containing 4 mol/L guanidinium isothiocyanate, 0.5% sarcosyl, 5 mmol/L sodium citrate (pH 7.0), 100 mmol/L p-mercaptoethanol, and 0.1% antifoam A emulsion (Sigma). The platelet lysate was either frozen at -8o"C, or layered immediately onto a 1.2 mL cushion of 5.7 mol/L CsCl in TE (10 mmol/L Tris-HCl, 1 mmol/L EDTA, pH 8.0), and subjected to centrifugation at 36,000 rpm for 18 hours at 20°C in a Beckman SW 50.1 rotor (Beckman Instruments, Palo Alto, CA). Pelleted RNA was dissolved in For genomic DNA isolation, leukocytes were washed once in Hanks' Balanced Saline Solution (HBSS; GIBCO BRL, Gaithersburg, MD) to reduce red blood cell contamination, and then lysed at room temperature in 10 mL of a solution containing 0.32 mol/L sucrose, 5 mg/mL MgCl,, 1% Triton X-100, and 10 mmol/L Tris-HC1 (pH 7.5). After obtaining a crude nuclear pellet by centrifugation (90% for 10 minutes), nuclei were lysed by adding 1.88 mL of a solution containing 400 mmol/L NaCl, 2.0 mmol/L EDTA, 10 mmol/L Tris-HC1 (pH 8.2), 125 pL of 10% sodium dodecyl sulfate (SDS), and 315 pL of 1 mg/mL of proteinase K (United States Biochemicals, Cleveland, OH) and incubating in a shaking 37°C waterbath overnight. After adding 625 pL of NaClsaturated H,O, particulate material was pelleted by centrifugation (6,OOOg for 10 minutes) and discarded. Genomic DNA was precipitated from the supematant by adding 2 vol of EtOH, and recovered by spooling on a glass capillary tube. After adding 500 pL of TE, the DNA solution was extracted sequentially with equal volumes of phenol, phenol/chloroform, and chloroform, and then EtOHprecipitated. DNA was recovered by centrifugation (10,00Og), resuspended in 500 pL of TE, and stored at -20°C.
Reverse transcription of approximately 0.15 pg of purified platelet RNA was performed at 37°C for 1 hour in the presence of 100 pmol of vWF antisense primer a4542-4530 (GAAGTCGGCTTCA), and 100 U of reverse transcriptase (BRL) in a final reaction volume of 50 pL that included 40 U of RNasin ribonuclease inhibitor (Promega), 0.5 mmol/L each dATP, dCI", dGTP, dTTF' , 0.1 pg/pL bovine serum albumin (BSA), and 10 pL of 5X reverse transcriptase buffer (GIBCO BRL, Gaithersburg, MD). The complete reaction mixture was placed in an Ericomp Cyclic Reactor, and RNA/DNA complexes were denatured by incubating for 5 minutes at 94°C. The reaction was cooled to 51T, and DNA amplification was initiated by adding 100 pmol each of vWF sense primer s3544-3573:Sal I (ATCgTcGAc-GAGC'I-ITTGCAGACCTGCGTT) and antisense primer a4506-4480flco I (GACGAACGCCACATCCAGAACCATGGA), 5 pL of 1 mg/mL BSA, 2.5 U of Taq DNA polymerase (Perkin Elmer Cetus), in a final reaction volume of 100 pL. Lower-case letters in the primer sequences indicate nucleotides that differ from the corresponding vWF sequence for the purpose of introducing restriction sites into the amplified DNA. (Nucleotide one of vWF corresponds to the A of the codon for the initiating methionine, and amino acid one corresponds to the first amino acid of the mature protein.) Amplification was continued for 30 cycles, with each cycle consisting of 2 minutes at 72"C, 1 minute at 94T, and 2 minutes at 53T, concluding with 7 minutes of incubation at 72°C. To enhance recovery of amplified DNA, 1.0 pL of the first-round PCR reaction was used in a second PCR reaction under the same conditions, except that internal sense (~3598-3627:Nsi I, GAGaTGcaTGGCCGGCG'ITTTGCCTCAGGA) and antisense (a4488-4462flco I, AACCATGGAG'ITCCTCCTGGGCCCCAG) primers were added. The 891-bp fragments produced by second-round PCR were digested with Nco I and Nsi I, purified after agarose gel electrophoresis using the Geneclean kit (BIO 101; La Jolla, CA), and inserted into the Nco I and Nsi I sites of pGEM-SZf(+) (Promega). The sequence of the vWF Nco I/Nsi I insert in individual clones was determined with Sequenase 2.0 (GIBCO-BRL) using mini-prep DNA. For one unaffected family member, the sequence of the vWF GPIb-binding region was determined Amplification and cloning. from amplified, cloned genomic DNA. In this instance, only one round of PCR was performed, and amplification was primed with oligonucleotides VsI27-1 (TGGGAATATGGAAGTCATTG) and a4506-448ONco I. Primer VsI27-1 is complementary to sequence in vWF intron 27." The amplified DNA was digested with Nco I, and inserted into EcoRVINco I-digested pGEM-5Zf( +). A minimum of five clones from each individual was sequenced. Nucleotide substitutions linked to type IIB vWD were confirmed by identification of the identical mutation in clones from the same patient derived from a separate PCR reaction, and in clones from affected, but not unaffected, family members.
COS-7 cells (ATCC No. CRL 1651; ATCC, Rockville, MD) were maintained at 37°C in a 5% CO,, humidified chamber in Dulbecco's modified Eagle media (DME) supplemented with 10% fetal calf serum and 2 mmol/L L-Gln. Using a two-step cloning procedure, the Sau IINco I fragment in vWF expression vector pvW198 was replaced with the corresponding fragments from clones p441JR and p387DS, which contain the amplified DNA representing the mutant vWF allele B of patients 111.3 and B1, respectively, resulting in the vWF expression plasmids pvW198.5 and pvW198.6. Expression plasmids were introduced into COS-7 cells in the presence of lipofectin (GIBCO BRL), following the protocol of Felgner et al.14 In brief, 1 x le cells were plated in 60-mm dishes and grown overnight. After washing the cells twice with HBSS, 3.0 mL of OPTI-MEM-reduced serum media (GIBCO BRL) containing 50 pg of lipofectin and 10 pg of the appropriate plasmid DNA was added, and the cells were incubated at 37°C for 6 hours. Transfected cells were washed once with HBSS, 3 mL of culture media was added, and incubation was continued at 37°C for 48 hours. Conditioned media was harvested, cleared by centrifugation at 10,OOOg for 10 minutes at 5"C, and then stored at -80°C. In some experiments, expressed protein was labeled metabolically from 48 to 72 hours posttransfection in the presence of 200 pCi/mL each of [%]Met and [35S]Cys (ICN Biomedicals, Costa Mesa, CA) in serum-free DME media lacking Met and Cys (GIBCO BRL). vWF constitutively secreted by cultured human umbilical vein endothelial cells ( H W E C ) was similarly labeled.
Metabolically labeled pro-vWF, mature vWF, and VW AgII were immunoprecipitated from conditioned media using monoclonal antibody (MoAb) AvW115 and MoAb MBC33.516 coupled to Sepharose CL-4B, and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE)17 in the presence of P-mercaptoethanol. The multimeric structure of immunoprecipitated vWF was determined by electrophoresis in nonreducing 0.65% agarose gels in the presence of SDS.4 The binding of plasma vWF to platelets was determined using the platelet-binding assay developed by Scott and Montgomery.18 Because of high background due to COS cell growth medium, and because of the low concentration of expressed vWF in conditioned media, a modified version of this procedure was used to determine the binding of expressed vWF to platelets. For the modified assay, 100 pL of conditioned media, or pooled normal plasma diluted in barbital-buffered saline (10 mmol/L sodium barbital [pH 7.41, 125 mmol/L NaCl), was added to 1 x lo7 formalin-ked platelets (Bio/Data Corp, Hatboro, PA) in the presence or absence of ristocetin, and incubated undisturbed at room temperature for 1 hour. PlateWvWF complexes were pelleted by centrifugation (10,OOOg for 10 minutes), and the amount of vWF remaining in each supernatant was determined by quantitative immunoelectrophoresis" using lZSI-labeled AvWl for detection. The autoradiographs in Fig 5 were scanned with a Bio-Rad Model 620 Video Densitometer and analyzed using the Bio-Rad 1-D Analyst I1 software (Bio-Rad, Richmond, CA).
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RESULTS
~u r~~o~ in type iB3 vWD patiem. Figure 1 shows the pedigree of a family with individuals with a mild bleeding disorder diagnosed as type IIB vWD. Consistent with this diagnosis, the plasma from affected individuals was determined to be within the normal range for APTT, factor VIIIC activity, vWF antigen level, and vWF activity, bur was lacking the high mw vWF multimers. In addition, the platelet-rich plasma from these patients aggregated in the presence of low doses of ristocetin. The diagnosis of p l a~e l e t -~e vWD in these ~ndivjduals was excluded by a ristocetin-dependent platelet-binding assay that showed that, unlike normal vW, the remaining low and intermediate mw plasma vWF multimers bound to normal platelets in the presence of low con~ntrations of ristocetin (Fig Z) , and by the failure of normal plasma or cryoprecipitate to induce aggregation of the patient's platelet-rich plasma.
To further understand the in~eraction between vWF and GPIb at the molecular level, and to determine whether defects in this interaction are the sole basis for the expression of type IIB vWD, we isolated total platelet RNA from both affected and normal individuals and used reverse transcription and PCR to amplify the segment of vWF messenger RNA ( " A ) encoding the GPIb binding d~main.~'~ We included in this analysis an unrelated patient, named B1, also affected by type IIB vWR. Amplified DNA was digested with Nco I and Nsi I and cloned into the ~mpatibIe sites of pGEM-SZf(+), The cloned VW fragments spanned nucleotides 3697 to 4479, which encode amino acids GIym to
The results of sequence analysis of the cloned PCR products of two family members with type IIB vWD, patients AIL5 and AII1.3, and patient B1, are presented in Fig 3 . Two missense m u t a t i o~ within the ampli~ed region were identified in family A, compared with the vWF cDNA sequence in the vWF expression vector p~W 1 9 8 .~ One mutation, a C + T transition at nucleotide 4010 that results in the substitution of Leu for Prd74, was present in vWF alleie B of patient AILS. This mutation was present in the mRNA isolated from the other three affected individuals in family A, but not in the mRNA isolated from unaffected family members. The other mutation that was identified, a G 3 A transition at nucleotide 4141, was present only in of mature vWF. (Fig 4, lane 5) .
To assess the multimeric nature of expressed vWF, 35S-labeled proteins were analyzed by electrophoresis in nonreducing 0.65% SDS agarose gels. The multimeric structure of expressed wt and mutant vWF is similar, although only smaller multimers consisting of on average five to six vWF dimer molecules accumulated in the conditioned media of all transfected cells (data not shown). This is in contrast with the vWF secreted by cultured HUVEC, where multimers containing up to 10 vWF dimer molecules can be seen by our methods of analysis.
One clinical characteristic of type IIB vWD is the heightened interaction between plasma vWF and platelets in the presence of the antibiotic ristocetin. To determine whether the Pro'" --* Leu or Va'53 + Met substitutions in vWF.5 and vWF.6, respectively, altered this interaction, we tested the ability of expressed vWF to bind to platelets in the presence or absence of ristocetin using a modification of an assay developed by Scott For diluted normal plasma, no binding of vWF to platelets was observed in the absence of ristocetin, and only negligible binding (4%) was observed in the presence of 0.075 mg/mL ristocetin (Fig 5A) . Binding of vWF to platelets increased to 17% in the presence of 0.15 mg/mL ristocetin, and to 63% in the presence of 0.3 mg/mL ristocetin. With ristocetin present at 0.6 or 1.2 mg/mL, complete binding of plasma vWF to platelets was observed, resulting in the loss of vWF from the supernatant and the corresponding absence of a signal in our assay. When diluted normal plasma is incubated with 1.2 mg/mL ristocetin in the absence of platelets, nonspecific precipitation of vWF resulted in the loss of 45% of the vWF (Fig 5A) . However, the complete loss of vWF from the supernatant in the presence of ristocetin is platelet-dependent, and is not due to ristocetin-induced protein precipitation?' The ristocetin-dependent platelet-binding profile of expressed wt vWF was similar to that seen for normal plasma vWF, except that expressed wt vWF was slightly less sensitive to low concentrations of ristocetin (Fig 5B) . No binding of wt vWF to platelets was detected in the absence of ristocetin, and binding in the presence of 0.075 or 0.15 mg/mL ristocetin was negligible (4%). With ristocetin present at 0.3 mg/mL, 18% of the wt vWF bound to platelets. The binding of wt vWF to platelets increased sharply to 78% and 90% when ristocetin was present at 0.6 and 1.2 mg/mL, respectively.
Expressed mutant proteins vWF.5 (Pro574 + Leu) and vWF.6 (Valss3 + Met), however, showed a platelet-binding profile that was significantly different than that of expressed wt vWF (Fig 5C) . Both vWF.5 and vWF.6 showed spontaneous binding to platelets, with vWF.6 being the most reactive. In the absence of ristocetin 61% of vWF.6 bound to platelets, compared with 16% bound for vWF.5. With ristocetin present at 0.075 mg/mL, the amount of vWF.6 and vWF.5 bound to platelets increased to 81% and 67%, respectively. For both mutant proteins, maximal binding to platelets occurred with ristocetin present at 0.3 mg/mL, or higher concentrations. Unlike plasma vWF, the presence of ristocetin at 1.2 mg/mL in the absence of platelcts did not induce precipitation of either expressed mutant or wt vWF.
This most likely reflects differences in the total protein comprising plasma and conditioned media.
To show that the ristocetin-dependent interaction observed involves platelet GPIb and vWF, supernatants containing vWF or platclets were incubated with anti-vWF MoAb AvW3" or anti-GPIb MoAb APl," respectively, before performing the ristocetin assay. AvW3 and APl each 
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tions on expressed full-length vWF were not reported, Ware et alZ7 expressed a recombinant fragment of vWF spanning amino acids Vala9 to Lysn8 that contained a type IIB-linked Cys substitution at position 550. In an indirect binding assay, this fragment showed spontaneous binding to platelets in the absence of ristocetin, and in the presence of ristocetin, showed a 10-fold higher affinity for platelets than the expressed wt fragment.
The reported type IIB amino acid substitutions are clustered within 35 amino acids of one another, and reside near the NH,-terminal end of the C y~'~-C y s~~~ loop, indicating that this region plays a central role in the interaction of vWF with GPIb. In other studies, Mohri et aIz8 have shown that the disulfide-linked vWF proteolytic fragment III-T2= binds to GPIb in the absence of ristocetin. This fragment is a homodimer of four chains in which a significant portion of the C y~~" -C y s~~~ loop has been removed by proteolysis. Interestingly, the deleted region (residues 512 to 673) includes the segment encoding all of the reported type IIB polymorphisms, suggesting that, while the loop may not be required for GPIb binding, it may influence the reactivity, or accessibility, of the GPIb binding site. The overlap between fragment 111-T2 and the GPIb-binding proteolytic fragments of Fujimura et a17xs and Andrews et a19 suggest that the vWF GPIb-binding site may be located in either residues 449 to 511 or 674 to 718. This is consistent with the report that two 15 amino acid peptides, corresponding to Cys474-Pro48s and L e~~~~-P r o '~ of vWF, both block GPIb binding by native vWF.'~ These peptide sequences are separated by 205 amino acids in the linear vWF sequence, and lie outside of the 185 amino acid loop. In the mature protein, however, these segments are in close proximity to one another, and to the polymorphic region, by virtue of the C y~'~-C y s~~' disulfide bond. In vivo, vWF is presumed to react with platelet GPIb after binding to subendothelial collagen in the presence of high sheer forces?' One of the two collagen binding sites mapped on vWF resides within the COOH-terminal portion of the Cyssw-Cys695 l 0 0 p . "~~~ Upon binding to collagen, a conformational change may occur in vWF that exposes the normally inaccessible GPIb binding site. A similar conformational change could be induced when Leu is substituted for within the same loop, as the loss of Pro, a strong turn-former, is likely to affect local secondary structure. However, only subtle changes in secondary structure may be required to unmask the GPIb-binding site, as the conservative substitution of Met for Val'53 also results in the heightened reactivity of vWF with GPIb.
Several studies suggest that charge interactions play an important role in maintaining the GPIb-binding site in an unreactive state under normal conditions. For example, asialo vWF exhibits spontaneous binding to GPIb,'3 most likely because the loss of sialic acid residues result in a protein that is less negatively charged than the normal protein. This alteration may affect the interaction of vWF with the platelet membrane, as well as cause changes in the secondary structure of vWF. The reactivity of asialo vWF with platelets supports a model in which interaction between the positively charged block the ristocetin-dependent binding of vWF to platelet GPIb. In the presence of 0.6 mg/mL ristocetin, both AvW3 and AP1 block the interaction between platelets and plasma vWF or expressed vWF (data not shown).
DISCUSSION
We report here the identification of two missense mutations in mature vWF associated with type IIB vWD. One mutation, which is stably inherited in an affected family, results in the substitution of Leu for Pro574. A different mutation, present in an unrelated individual with type IIB vWD, results in the substitution of Met for Val553. We further showed that each of these mutations confers to transiently expressed full-length, multimeric vWF enhanced reactivity with platelet GPIb in the presence of low concentrations of ristocetin, an essential diagnostic feature of type IIB vWD. In addition, the sensitivity of the two mutant expressed proteins to low doses of ristocetin paralleled the clinical expression of type IIB vWD in the affected individuals, supporting our conclusion that these amino acid substitutions are the molecular basis for disease expression.
The mutations that we identified reside in the A1 domain of mature vWF within a 185 amino acid loop defined by an intramolecular disulfide bond between Cys'" and C~S @ ' .~,~ The presence of the mutations in this region is consistent with analyses by Fujimura et aI7.' and Andrews et a19 that place the GPIb-binding domain of vWF between amino acids ValM9 and Gly7I8. While this work was in progress, five other missense mutations linked to type IIB vWD, including the Val5" + Met substitution, have been Although the effects of the resulting amino acid substitu-negatively charged carbohydrate at Asnag buries the vWF GPIb binding site so that GPIb binding does not occur. This is consistent with the proposed mechanism of action of ristocetin, an electropositive molecule that may promote vWF/platelet interaction through charge neutralization." Three of the reported missense mutations linked with type IIB vWD involve the loss of Arg, a basic amino and may induce vWF reactivity with platelets by a similar mechanism.
Our analyses show that expressed IIB vWF binds to platelets spontaneously, and is more sensitive to low doses of ristocetin than plasma vWF of the affected individuals. The greater reactivity of expressed IIB vWF with platelets is most likely due to the homozygous composition of the vWF multimers, which consist only of defective vWF. The affected individuals, however, are heterozygous for the mutations leading to the Val553 -+ Met and Pro574 + Leu substitutions, and thus synthesize multimers that contain a mixture of normal and defective vWF. In addition, although type IIB vWD individuals are capable of synthesizing the full size range of vWF multimers, the most reactive multimers are cleared from plasma after binding spontaneously to platelets, resulting in plasma that consists primarily of the less reactive low and intermediate mw multimers.
RNA PCR coupled with transient expression of fulllength vWF has proven to be a useful approach for the identification and analysis of missense mutations linked with the type IIB vWD. Information gained from the analysis of additional mutations will lead to a better understanding of the mechanisms that govern vWF/platelet interactions, will aid in the development of a nucleic acid-based system for the diagnosis of type LIB vWD, and will be useful in the identification of therapeutic reagents.
